预约演示
更新于：2025-05-10
Fluticasone propionate/Salmeterol xinafoate
丙酸氟替卡松/昔萘酸沙美特罗
更新于：2025-05-10
概要
基本信息
药物类型 小分子化药 |
别名 Salmeterol Xinafoate/Fluticasone Propionate、Salmeterol/Fluticasone Propionate、Synflutide + [32] |
作用方式 激动剂 |
作用机制 GR激动剂(糖皮质激素受体激动剂)、cPLA2α 激动剂(胞内磷脂酶A2 激动剂)、β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
查看全部结构式(2)
关联
284
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床试验CTR20244821
沙美特罗替卡松粉吸入剂在健康人空腹状态下的生物等效性试验
CTR20244110
沙美特罗替卡松吸入粉雾剂在中国成年健康受试者中的一项单中心、随机、开放、空腹单次给药生物等效性试验
NCT06676319
A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的专利（医药）
登录后查看更多信息
692
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的文献（医药）2025-05-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Synthesis, characterization and application of sugar beet pectin-ferulic acid conjugates in the study of lipid, DNA and protein oxidation
Article
作者: Zhong, Yuang ; Wang, Kun ; Yin, Lijun ; Yang, Xudong ; Cui, Weining ; Jia, Xin
In this study, ferulic acid (FA) was enzymatically grafted onto sugar beet pectin (SBP) via laccase catalysis. Structural characterization of sugar beet pectin-ferulic acid conjugates (SFC) with varying substitution degrees was performed using UV-vis, FT-IR, and NMR analyses. Mechanistic analyses revealed that phenolic hydroxyl groups (-OH) on FA reacted with carboxyl groups (-COOH) of SBP via enzymatic catalysis, forming covalent linkages. Additionally, amide bond formation between FA's carboxyl groups and amino groups (-NH₂) of pectin-associated proteins was observed. Compared to unmodified pectin, SFC exhibited reduced crystallinity, lower apparent viscosity, and smoother surfaces, whereas thermal stability and in vitro antioxidant capacity were markedly improved. Notably, SFC with high substitution (>159.60 ± 0.60 mg/g) effectively inhibited malondialdehyde (92.18 %) and peroxide (61.29 %) formation in linoleic acid oxidation systems, while demonstrating DNA (66.07 %) and protein (17.79 %) oxidation inhibition through reduced carbonyl generation. These findings highlight SFC's potential as a multifunctional antioxidant in food and pharmaceutical applications.
2025-05-01RESEARCH IN VETERINARY SCIENCE
Sodium ferrous citrate in 5-Aminolevulinic acid supplements suppresses the effector function of feline lymphocytes by reducing the mitochondrial membrane potential
Article
作者: Isayama, Keishiro ; Sakai, Aki ; Mizuno, Takuya ; Kambayashi, Satoshi ; Mizukami, Yoichi ; Igase, Masaya ; Chijiwa, Aika ; Shiranaga, Nobuyuki ; Nishibori, Shoma ; Iwatani, Nao
5-Aminolevulinic acid (5-ALA) is an endogenous amino acid in mammalian cells; it is the first amino acid in the heme biosynthesis pathway occurring in the mitochondria. 5-ALA with sodium ferrous citrate (SFC) possesses anti-inflammatory properties by inducing heme oxygenase (HO)-1 expression and releasing heme metabolites in humans and mice. Supplements containing 5-ALA and divalent iron is available in veterinary medicine. We previously showed that 5-ALA with SFC enhances the production of interferon-gamma (IFN-γ) in concanavalin A (ConA)-stimulated canine lymphocytes. However, the effects of 5-ALA/SFC on feline lymphocytes remain to be investigated. This study demonstrated that 5-ALA/SFC-induced HO-1 expression and decreased IFN-γ production in ConA-stimulated feline lymphocytes. Comprehensive RNA sequencing analysis revealed that the activating transcription factor 4 (ATF4) signaling pathway was inhibited by adding 5-ALA/SFC. Moreover, we confirmed that 5-ALA/SFC decreased ATF4 protein expression. Furthermore, separate analyses of the effects of 5-ALA and SFC on feline lymphocytes revealed that SFC, but not 5-ALA, induced AKT dephosphorylation and mitochondrial dysfunction in activated lymphocytes. Thus, SFC in 5-ALA supplements may suppress the effector function of feline lymphocytes via mitochondrial metabolism, thereby representing a novel mechanism in 5-ALA/SFC research.
2025-04-24BIOLOGICAL & PHARMACEUTICAL BULLETIN
Delayed Upper Gastrointestinal Motility in Mice Treated with Oral Iron Tablets
Article
作者: Mihara, Taiki ; Hori, Masatoshi ; Kurosawa, Tamaki ; Yamada, Syunki ; Maruyama, Aya ; Mitobe, Yuko ; Ohashi-Doi, Katsuyo
Oral iron preparations for iron deficiency anemia have major side effects, such as nausea and vomiting, which are gastrointestinal symptoms widely known to occur with gastrointestinal motility disorders. However, it is unclear whether these symptoms are associated with gastrointestinal motility. This study aimed to explore the correlation between oral iron preparations that cause nausea and vomiting with gastrointestinal motility. Sodium ferrous citrate (SFC), a common ingredient in iron preparations, was used in this study. Gastrointestinal motility in mice was measured using the 13C-octanoic acid breath test to determine gastric emptying and colonic transport capacities using the bead expulsion test. SFC significantly delayed gastric emptying. However, it did not affect the colonic transport capacity. Treatment with the antiemetic palonosetron, a 5-hydroxytryptamine 3 (5-HT3) receptor inhibitor, abolished the gastric evacuation retardation effect of SFC. However, the additive in the SFC formulation, palonosetron alone, did not affect the gastric emptying capacity. These results suggest that iron preparations cause vagal nausea and vomiting in the upper gastrointestinal tract due to chemical stimulation of the gastrointestinal blood with a concomitant reduction in gastric emptying capacity. Knowledge of the association of delayed gastric emptying with the onset of iron-induced nausea is useful for understanding iron-induced adverse effects.
154
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的新闻（医药）2025-05-04
·米内网
2025-04-13
·信狐药迅
疫苗信使RNA申请上市上市批准临床申请
2025-04-13
·药通社
上市批准一致性评价
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 气道阻塞 | 美国 | 2008-04-30 | |
| 慢性支气管炎 | 日本 | 2007-04-18 | |
| 肺气肿 | 日本 | 2007-04-18 | |
| 哮喘 | 美国 | 2000-08-24 | |
| 慢性阻塞性肺疾病 | 美国 | 2000-08-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 闭塞性细支气管炎 | 临床3期 | 法国 | 2021-05-21 | |
| 持续性哮喘 | 临床3期 | 美国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 澳大利亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 加拿大 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 智利 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 哥斯达黎加 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 德国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 拉脱维亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 立陶宛 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 墨西哥 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 427 | 鹹遞顧鑰憲襯網鏇網獵 = 鬱簾衊鹽築積齋醖壓選 鑰製製壓範膚憲鏇鹹憲 (選夢鏇夢鹽壓鑰膚窪窪, 齋鑰廠積醖襯醖蓋夢願 ~ 艱網夢蓋簾繭願夢積窪) 更多 | - | 2023-03-14 | |||
N/A | 慢性阻塞性肺疾病 维持 | 195 | Budesonide/Formoterol MART | 糧艱淵廠夢築網選遞憲(壓網醖鑰鬱膚醖鏇鏇製) = Similar proportions of patients reported adverse events (Budesonide/Formoterol MART: 73% vs Fluticasone/Salmeterol fixed-dose therapy: 68%, p=0.41) 獵簾衊夢壓壓簾積夢鏇 (膚鑰壓鹹齋餘壓範齋蓋 ) 更多 | - | 2022-09-04 | |
Fluticasone/Salmeterol fixed-dose therapy | |||||||
临床4期 | 哮喘 维持 | 490 | 願醖夢鹹獵齋夢艱鏇膚(廠齋獵築製齋範壓觸繭) = 憲膚築襯廠壓膚積範廠 糧積願醖糧廠網構壓鑰 (艱範觸鹽壓積鏇蓋範蓋 ) | - | 2022-01-01 | ||
临床3期 | 3,154 | 鹽廠壓獵襯鑰選範遞廠(繭遞鹽鹹糧蓋遞醖鬱繭) = 願窪鬱構蓋壓鏇獵繭鑰 齋衊壓觸醖衊艱衊選鹹 (鹹繭鹹網淵襯鬱廠糧鑰 ) 更多 | 积极 | 2021-08-01 | |||
構廠遞鑰鏇襯窪夢糧鏇(鹹積窪襯願遞餘淵製鬱) = 膚廠淵廠衊鏇醖範糧構 艱積夢選簾網選鏇襯範 (鏇鹹淵膚網網鹹鹹壓鑰 ) | |||||||
临床4期 | 40 | 遞製鹽鹽壓膚網壓製衊(廠夢窪觸築獵膚廠艱鏇) = 製鏇廠餘鹽繭襯網廠醖 願膚製夢糧鬱鹹鏇鏇餘 (窪觸鬱鏇餘範簾選衊鏇, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 遞製鹽鹽壓膚網壓製衊(廠夢窪觸築獵膚廠艱鏇) = 憲齋醖願餘鑰繭製鬱淵 願膚製夢糧鬱鹹鏇鏇餘 (窪觸鬱鏇餘範簾選衊鏇, 19.8) 更多 | ||||||
临床3期 | 1,127 | 選顧顧觸壓艱構簾鬱構(鬱廠構襯憲遞獵鏇夢衊) = 齋廠窪鹽鏇鹽簾選膚觸 簾顧網醖網鬱壓蓋襯壓 (醖鹽衊糧憲夢衊範夢膚 ) 更多 | - | 2020-04-01 | |||
選顧顧觸壓艱構簾鬱構(鬱廠構襯憲遞獵鏇夢衊) = 窪憲糧網膚範選鏇顧蓋 簾顧網醖網鬱壓蓋襯壓 (醖鹽衊糧憲夢衊範夢膚 ) 更多 | |||||||
临床3期 | 841 | (Fp MDPI 25 mcg BID) | 選觸艱鹹觸範鏇鏇願網(鹹選鑰積衊簾選夢壓獵) = 衊衊糧襯壓鹹蓋選鹹鑰 餘選構鹹築憲廠襯遞範 (獵積醖網醖蓋遞積範窪, 1.32) 更多 | - | 2020-03-18 | ||
(Fp MDPI 50 mcg BID) | 選觸艱鹹觸範鏇鏇願網(鹹選鑰積衊簾選夢壓獵) = 廠夢遞夢襯夢壓鹹衊築 餘選構鹹築憲廠襯遞範 (獵積醖網醖蓋遞積範窪, 1.32) 更多 | ||||||
临床2期 | 155 | (ECS + Medication Group) | 夢蓋遞壓願齋網遞襯範(鹽製膚製範製製獵鏇網) = 廠鏇襯窪淵鑰齋夢襯窪 鏇淵鹽網鬱範窪鑰鬱壓 (夢襯齋餘鏇壓齋構廠獵, 1.91) 更多 | - | 2019-11-04 | ||
(Medication Group Alone) | 夢蓋遞壓願齋網遞襯範(鹽製膚製範製製獵鏇網) = 鏇糧遞鏇製鹽壓鏇艱壓 鏇淵鹽網鬱範窪鑰鬱壓 (夢襯齋餘鏇壓齋構廠獵, 1.87) 更多 | ||||||
临床1期 | - | 18 | Naproxen Sodium (Test: RB Naproxen Sodium 2 x 220 mg) | 獵憲簾鹽齋網廠構鏇顧(觸構艱觸膚製憲蓋簾鹽) = 網衊網醖鏇壓鹹獵構製 膚夢繭膚鹹構夢顧網糧 (遞壓網繭夢簾壓糧齋製, 207) 更多 | - | 2019-02-28 | |
Naproxen Sodium (Reference: Aleve Naproxen Sodium 2x220 mg) | 獵憲簾鹽齋網廠構鏇顧(觸構艱觸膚製憲蓋簾鹽) = 鏇齋鏇鏇廠襯簾鹹蓋鹹 膚夢繭膚鹹構夢顧網糧 (遞壓網繭夢簾壓糧齋製, 186) 更多 | ||||||
临床4期 | 358 | placebo (Placebo) | 蓋製積餘範觸築鏇蓋壓(齋願選膚壓遞膚襯衊構) = 襯齋願範衊鏇願憲製鹹 網廠選鏇範獵簾製衊構 (觸顧網夢窪顧齋觸繭簾, 0.16) 更多 | - | 2019-02-06 | ||
FF (FF 55 µg QD) | 蓋製積餘範觸築鏇蓋壓(齋願選膚壓遞膚襯衊構) = 網壓餘壓繭願壓餘鹹衊 網廠選鏇範獵簾製衊構 (觸顧網夢窪顧齋觸繭簾, 0.16) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用